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the syndrome sometimes affects the joints and bones of the
upper limbs, which are more rarely subject to micro-
trauma, or at least more rarely subject to microtraumas,
which affect all of the joints contemporaneously. What is
more, the facts that therapy with non-steroidal anti-
inflammatory drugs has not been effective and that the
calcium channel blockers which likely reduce intraosseus
hypertension are successful in treating bone and joint
pain7,8 both support Grotz’s theory.
The two hypotheses therefore seem to be equally
plausible, and it is possible that it is a multifactorial
syndrome in which the drug-related intraosseus hyperten-
sion may be associated with repeated microtraumas. Only
a bone biopsy during the acute phase (ethically debatable)
could resolve the question.
What is clear is that it is not a reflex sympathetic
dystrophy syndrome as some authors still claim, but rather
that it is a syndrome in itself, which resolves spontaneously
and in which the use of non-steroidal anti-inflammatory
drugs is contraindicated.
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To the Editor: The renal community has recently enjoyed a
spirited reexamination of the role of angiotensin converting
enzyme inhibitors (ACEIs) in the treatment of chronic kidney
disease. The core renal concept of the effectiveness of ACEIs
has been challenged in Kidney International by Suissa et al.,1
several subsequent letters (Kidney Int, volume 70, October
2006), a previous meta-analysis, and results from the
ALLHAT study. These criticisms have elicited several vigorous
counter-responses.2,3
This debate appears to presume that ACEIs have been
optimally used, both in clinical studies and in the commu-
nity. If ACEIs can be prescribed in more effective manner,
there are implications for both viewpoints.
The defense of ACEIs is based on several carefully
performed large studies. Though convincing to many, it
should be noted that the statistically significant renal
protection demonstrated by either ACEIs or angiotensin 2
type 1 receptor blockers, as compared with controls, was
clinically modest. Twenty to forty per cent of treated patients
typically doubled their serum creatinine levels within
relatively short follow-up periods. Even supporters of
renin–angiotensin system (RAS) blockers must concede that
the mere prescription of an RAS blocker is an ineffective
therapy for too many patients.
However, it is possible that these modest results (or the
absence of any favorable result in other analyses) may derive
in part from the manner in which RAS blockers have been
prescribed. Brenner and others have recommended a
different approach to RAS blocker prescription, which was
subsequently termed ‘flexible and goal-oriented’ and re-
viewed in detail.4 This approach recognizes that lowering
blood pressure and urinary protein loss provides continually
increasing renal protection until the levels of B120 mm Hg
systolic (perhaps lower) and 300–500 mg proteinuria per day,
respectively. Therefore, the goal-oriented approach recom-
mends that both of these goals must be achieved in order to
presume optimal renal prognosis.
In no study of RAS blockers to date, have patients
consistently reached both goals. Clearly, more intensive RAS
blockade than previously prescribed is needed to reach these
stringent goals: multiple, complementary RAS blockers,
higher doses, and considerable effort. Moreover, interindivi-
dual variations in the ACEI insertion/deletion genotype, and
in other factors, make it unlikely that a single protocol or
approach will be broadly effective. Recognizing this, the goal-
oriented approach de-emphasizes broadly applied protocols.
Instead, it proposes a more flexible approach to RAS
blockade and hypertension that addresses interindividual
variations.
The evaluation of whether ACEIs (or RAS blockers in
general) are effective treatment for chronic kidney disease
should consider whether improved results might be obtained
with different strategies.
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